Invention Grant
- Patent Title: Method for utilizing engineered dendritic cells to induce gut-homing regulatory T cells and treat gut inflammation
-
Application No.: US15550501Application Date: 2016-02-11
-
Publication No.: US10577669B2Publication Date: 2020-03-03
- Inventor: Xiaolei Tang , David J. Baylink , K.-H. William Lau , Michael Walter
- Applicant: Loma Linda University
- Applicant Address: US CA Loma Linda
- Assignee: Loma Linda University
- Current Assignee: Loma Linda University
- Current Assignee Address: US CA Loma Linda
- Agency: Womble Bond Dickinson (US) LLP
- International Application: PCT/US2016/017610 WO 20160211
- International Announcement: WO2016/130845 WO 20160818
- Main IPC: C12N5/0784
- IPC: C12N5/0784 ; C12N9/02 ; A61K38/44 ; A61K35/15 ; A61K48/00 ; C12P19/34
Abstract:
Gene-modified, lymphoid-tissue-homing dendritic cells that comprise a 1-alpha-hydroxylase gene and a retinaldehyde dehydrogenase 2 gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme and the retinaldehyde dehydrogenase 2 gene is expressed to produce functional retinaldehyde dehydrogenase 2 gene enzyme. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, lymphoid-tissue-homing dendritic cells that comprise a 1-alpha-hydroxylase gene and a retinaldehyde dehydrogenase 2 gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme and the retinaldehyde dehydrogenase 2 gene is expressed to produce functional retinaldehyde dehydrogenase 2 gene enzyme.
Public/Granted literature
Information query
